At the end of January, Russians are available two vaccines from Kovid domestic production - "Satellite V" of the Institute of Gamalei and Epivakkoron Center "Vector". Vaccination is the most massive.
Two more vaccines expect registration in the Russian Ministry of Health: the domestic "Kovivak" center named after Chumakov RAS and the Chinese "Convidence". Read details about these and other candidate vaccines in our guide.
"Satellite V" ("Gam-Kovid-Vac")Country Russia.
Developer: NIC epidemiology and microbiology them. N. F. Gamalei Ministry of Health of Russia.
Vaccine type: two-component vector vaccine. The vaccine is introduced twice, with an interval of three weeks.
How it works: adenovirus removed the reproduction gene and placed a gene that encodes the S-protein of the spike coronavirus. With the help of S-protein, the coronavirus gets into the cage.
Adenovirus, which is engaged in transporting "training material" for the immune system, a well-known person - he causes ordinary ARVI. The vaccine is a two-mector, because it uses two types of adenovirus: two injections are made so that at least one of them is probably through the immune defense of the body.
Storage conditions: -18.
Efficiency: According to the results of interim studies, the effectiveness of the "satellite V" is 91.4%, against severe cases of the disease - 100%. Immunity is produced three weeks after the introduction of the second component of the vaccine.
Side effects: chills, elevated temperature, headache, as well as a decrease in appetite and an increase in lymph nodes.
Vaccination in Russia: began on December 5, 2020. Vaccination can be done free.
The need for revaccination: It is expected that immunity will be formed for two years.
Stage: Clinical studies of the third phase continue. The vaccine received temporary registration of the Ministry of Health of Russia on August 8, 2020. In early January, the Ministry of Health issued permission to the Gamalei Center for clinical trials of the single-component version of the preparation "Satellite V", Satellite Satellite Vaccines.
Clinical studies: "Satellite V" is checked with a double, blind randomized placebo-controlled clinical study *. The number of clinical trial participants with the permission of the Ministry of Health is reduced from 40,000 to 31,000 people. Of these, 25% will receive placebo. The press service of the RDIA, who oversees the creation of the vaccine, did not respond to the question of Vtimes about the publication of the final results of the third phase in international medical journals.
Manufacturers: "Binnofarm", "Generium", "Biocad", Branch "Medgamal" Nicem them. N. F. Gamaley. Later, "R-Farm", "Pharmacezinz" can join them.
According to Prime Minister Mikhail Mishoustina, it is planned to produce almost 6.5 million doses of vaccine per month.
* Gold Standard for conducting research
Vaccine Center "Vector" ("Epivakkoron")Country Russia.
Developer: State Scientific Center for Virology and Biotechnology "Vector" Rospotrebnadzor.
Vaccine type: peptide antigens-based vaccine. It is injected twice, intramuscularly with an interval of three weeks.
How it works: the vaccine consists of short sections of viral protein - peptides needed to form an immune response.
Storage conditions: 2-8 ° C (conventional refrigerator conditions).
Efficiency: The interim report will be released in early February. Cellular immunity is produced in a month and a half after the introduction of the vaccine.
Side effects: short-term pain in the injection site.
The need for revaccination: every three years.
Stage: Go clinical studies. Vaccine received temporary registration of the Ministry of Health on October 13th.
Vaccination in Russia: began. Vaccination can be done free.
Clinical studies: two studies are held. The first is a multicenter, double, blind placebo-controlled comparative randomized study * with the participation of 3000 volunteers aged 18 years (third phase). It is planned to be completed at the end of July 2021.
The second is an open study of the safety, reactogenicity and immunogenicity of vaccine with the participation of volunteers aged from 60 years and older (third phase). It will end at the end of January, and the observation of volunteers will continue within six months.
Manufacturers: State Scientific Center for Virology and Biotechnology "Vector" Rospotrebnadzor. The company "Gerofarm" will produce one of the key components of the vaccine - carrier protein. The large-scale production of the vaccine will be deployed in February.
* Gold Standard for conducting research
"Convidence" (AD5-NCOV)Country: China.
Developer: CANSINO BIOLOGICS INC.
Vaccine type: recombinant vaccine. Entered once.
How it works: the vaccine uses the platform of the adenoviral vector of the person carrying the coronavirus s-protein. This vector acts as a "delivery means", and the S-protein is an antigen to which the immune response is produced.
Storage conditions: 2-8 (conditions of the usual refrigerator).
Efficiency: The interim results of the local clinical study of the third phase showed the effectiveness of the vaccine at the level of 92.5%. The volunteer volunteers from 500 probaccinated were analyzed. Cellular immunity occurs in the first 14 days.
Side effects: 34.2% of volunteers have a small temperature, headache, pain in the joints or muscles, fatigue, which took place during the first few days.
Vaccination in Russia: did not start.
The need for revaccination: no data.
Stage: In Russia, the vaccine passes through the third phase of international clinical trials, a set of volunteers. Submitted documents for registration in the Ministry of Health of Russia.
Clinical studies: international, double, blind randomized placebo-controlled study *. In total, more than 40,000 volunteers will take part in it, 8,000 of them will be from Russia.
Manufacturer: After registering the vaccine, the Russian company "Petrovaks" is ready to launch vaccine production at the plant in the Moscow region. The beginning of production is scheduled for 2021, Vtimes stated in the press service of the company.
* Gold Standard for conducting research
Vaccine named after Chumakov RAS ("Kovivak")Country Russia.
Developer: Federal Scientific Center for Research and Development of Immunobiological Preparations. M. P. Chumakov RAS.
Vaccine type: solidarion.
How it works: "killed" is introduced to generate immunity, but the virus preserved antigenic properties.
Storage conditions: 2-8 ° C (conventional refrigerator conditions).
Efficiency: no data. Entered twice, with an interval of 2-3 weeks.
Side effects: unwanted phenomena after vaccination 200 volunteers have not been detected.
The need for revaccination: no data.
Stage: The clinical studies of the second stage on healthy volunteers between the ages of 18 and 60 are completed in January. The third phase of the test is expected in March 2021. It is planned to include about 3,000 people. Vice Prime Minister Tatyana Golikov expects vaccine registration in mid-February.
Vaccination in Russia: did not start. The release of the first series of vaccines is planned in the second half of March.
Clinical studies: research is unknown.
Manufacturer: Center for them. Chumakov prepared the production site. The company is negotiating with Nanolak, Vtimes reported in the press service of the latter. The first batch of vaccine from the center of them. Chumakov will contain 100,000 doses. Production platform will allow 10 million doses per year to produce 10 million doses.
Oxford Vaccine (AZD1222)Country: United Kingdom.
Developer: Astrazeneca together with Oxford University.
Vaccine type: two-component vaccine based on adenoviral vector. Two doses are introduced.
How it works: A weakened version of the ARVI chimpanzee virus, which cannot multiply, contains a genetic material of the spike coronavirus protein. After vaccination, the synthesis of the surface spit-shaped protein occurs and the immune response is formed.
Storage conditions: 2-8, vaccine is six months.
Efficiency: according to the intermediate analysis of the third phase of the study published in the LanCet journal, with the introduction of the volunteers of two complete doses of the vaccine, 62.1% is effective, and with the introduction of half and complete dose - in 90% of the participants in the study. Intermediate results are based on clinical studies conducted in the UK and Brazil with the participation of 11,636 volunteers, among which 131 cases of infection of COVID-19 were identified.
Side Effects: Temporary pain at the injection site, weakness and fatigue, headache, fever and muscle pain.
Vaccination in Russia: not started, there are no approximate dates.
The need for revaccination: no data.
Stage: Vaccine clinical studies continue all over the world: in the UK, USA, Brazil, South Africa, Japan, Kenya. It is planned to conduct research on the Oxford vaccine combined with another vaccine. According to the Global Clinical Trial Database of Clinical Trials, the test in Russia has been suspended.
Clinical studies: double, blind, multicenter randomized controlled studies * in which up to 60,000 volunteers of different age, racial, ethnic and geographical groups participate.
Manufacturer: On the territory of Russia, the Vaccine will produce R-Farm.
* Gold Standard for conducting research
Will the developers of other candidate vaccines from Kovid go to Russia?American-German matrix RNA vaccine from Pfizer & Biontech: Pfizer is considering the possibility of filing an application for registration of a candidate vaccine against COVID-19 in Russia, but there is no exact date.
American matrix RNA-vaccine MRNA-1273 from Moderna: At the end of December, the branch of the Israeli Hadassah hospital in Skolkovo, who has the right to use the drugs unregistered in Russia, announced the negotiations on the supply of Pfizer and Moderna vaccines to Russia. The clinic led the record of those who wanted to vaccinate into the "waiting list".
Later in Roszdravnadzor, they stated that imported vaccines to Russia, which did not undergo state registration in the country were prohibited. This also applies to the special zone - the International Medical Cluster in Skolkovo. On the hot line of Hadassah, Vtimes correspondent reported that the entry to the "Waiting list" on vaccination from Covid was stopped. The company Moderna published has not yet answered the question about the plans to go to Russia.
JANSSEN Vaccine based on Adenovirus 26 type (Johnson & Johnson): According to the managing director "Jansen" Russia and CIS Caterina Puekodina, at this stage the company is focused on the completion of vaccine clinical studies.
American recombinant Vaccine from MSD: On January 25, the company stated that it ceases to develop two experimental vaccines against Covid, as they could not cause an immune response, comparable to existing vaccines or response after a natural infection. In September, the Mariinsky Hospital in St. Petersburg declared a set of volunteers for the tests of the MSD vaccine. Currently, their search is completed, told the clinic. In the Russian representation MSD abandoned the comment.
Franco-British Adjuvant Recombinant Vaccine from Sanofi / GSK: There is no data on exit to Russia. Sanofi did not comment on the possible supply of vaccines to Russia.
British vaccine from British American Tobacco, created using tobacco raw materials: in the Global Press Service Bat Vtimes stated that the first phase clinical study was still only in the United States. In later stages, the participation of more volunteers will be involved, but the locations of these studies are not yet defined. The company assured that in the case of successful vaccine results, it can be provided to any government. And its availability will depend on the approval of national regulatory bodies and state procurement.
- Chinese inactivated Coronavac vaccine from Sinovac Biotech
- Chinese inactivated vaccine from China National Biotec Group, SINOPHARM divisions
- American recombinant protein novavax vaccine
- The American DNA Vaccine INO-4800 from Inovydata about the exit of these vaccines to Russia is not. The companies did not respond to the VTIMES request.
During the preparation of the material, the data provided by VTIMES press services "Petrovaks", "Astraseneca", Pfizer, Sanofi, MSD, BAT and Rospotrebnadzor; as well as information from the sites of pharmaceutical and resources "Stopcornavirus", clinical trials; Materials of publications Bloomberg, RBC, TASS, Vademecum, Interfax and Russian Gazeta.